Insu Yilmaz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Insu Yilmaz has a total of 315 co-authors. Here are the top co-authors by number of shared publications:
- Murat Türk
Division of Allergy and Clinical Immunology, Erciyes University School of Medicine, Kayseri, Turkey
34 shared publications - Gülden Paçacı Çetin
Department of Chest Diseases, Division of Allergy and Immunology, Erciyes University, School of Medicine
18 shared publications - Bahar Arslan
Division of Allergy and Clinical Immunology, Urticaria Center of Reference and Excellence (UCARE), Erciyes University School of Medicine, Kayseri, Turkey
17 shared publications - Nuri Tutar
Erciyes Universitesi
11 shared publications - Ömür Aydın
Ankara University Faculty of Medicine, Department of Chest Diseases, Division of Immunology and Allergic Diseases, Ankara, Türkiye
11 shared publications - Dilsad Mungan
Department of Chest Disease, Division of Immunology and Allergy, Ankara University School of Medicine
10 shared publications
Latest Publications
- Open Access
- 1 March 2026
- Published by Codon Publications in Allergologia et Immunopathologia
- Vol. 54 (2) , 35-44
Uncovering Type 2 inflammatory profiles in severe eosinophilic asthma with nasal polyps: the role of transcript-protein ratios and Staphylococcus aureus enterotoxin B-specific IgE
Background: Severe eosinophilic asthma with nasal polyps (SEAwNP) is a clinical phenotype characterized by elevated peripheral eosinophil counts and heightened type 2 (T2) inflammation. Objective: In this study, we aimed to compare the transcript/protein expression ratios of factor XIII-A (F13A), B-cell activating factor (BAFF), interleukin-5 (IL-5), and thymus- and activation-regulated chemokine (TARC), as well as serum Staphylococcus aureus Enterotoxin B-Specific IgE (SEB-IgE) levels, among patients with SEAwNP, SEA without nasal polyps (NP), NP without asthma, and healthy controls groups. Material and Methods: A total of 73 participants were enrolled and stratified into four groups: SEAwNP (n=20), SEA without NP (n=18), NP without asthma (n=15), and healthy controls (n=20). Peripheral blood samples were analyzed using real-time quantitative PCR and protein levels using ELISA for periostin, F13A, BAFF, IL-5, and TARC. Serum SEB-IgE levels were also assessed. Results: SEAwNP patients exhibited significantly elevated transcript/protein expression ratios of periostin, F13A, BAFF, and IL-5 compared to SEA without NP (p=0.007, p=0.001, p=0.019, and p=0.017, respectively). Furthermore, periostin, F13A, BAFF, IL-5, and TARC transcript/protein ratios were significantly higher in SEAwNP patients compared to healthy controls (p=0.0001, p=0.001, p=0.003, p=0.014, and p=0.02, respectively). SEB-IgE positivity rates were 45% in SEAwNP, 38% in SEA without NP, 13% in NP without asthma, and 0% in healthy controls. Conclusion: SEAwNP is associated with elevated transcript/protein expression ratio of key T2 inflammatory mediators and increased SEB-IgE positivity, supporting their potential role in the immunopathogenesis of this phenotype. These findings underscore the importance of biomarker profiling in distinguishing endotypes within the spectrum of eosinophilic airway diseases.
- 1 March 2026
- Published by Codon Publications in Allergologia et Immunopathologia
- Vol. 54 (2) , 35-44
Open AccessUncovering Type 2 inflammatory profiles in severe eosinophilic asthma with nasal polyps: the role of transcript-protein ratios and Staphylococcus aureus enterotoxin B-specific IgE
Background: Severe eosinophilic asthma with nasal polyps (SEAwNP) is a clinical phenotype characterized by elevated peripheral eosinophil counts and heightened type 2 (T2) inflammation. Objective: In this study, we aimed to compare the transcript/protein expression ratios of factor XIII-A (F13A), B-cell activating factor (BAFF), interleukin-5 (IL-5), and thymus- and activation-regulated chemokine (TARC), as well as serum Staphylococcus aureus Enterotoxin B-Specific IgE (SEB-IgE) levels, among patients with SEAwNP, SEA without nasal polyps (NP), NP without asthma, and healthy controls groups. Material and Methods: A total of 73 participants were enrolled and stratified into four groups: SEAwNP (n=20), SEA without NP (n=18), NP without asthma (n=15), and healthy controls (n=20). Peripheral blood samples were analyzed using real-time quantitative PCR and protein levels using ELISA for periostin, F13A, BAFF, IL-5, and TARC. Serum SEB-IgE levels were also assessed. Results: SEAwNP patients exhibited significantly elevated transcript/protein expression ratios of periostin, F13A, BAFF, and IL-5 compared to SEA without NP (p=0.007, p=0.001, p=0.019, and p=0.017, respectively). Furthermore, periostin, F13A, BAFF, IL-5, and TARC transcript/protein ratios were significantly higher in SEAwNP patients compared to healthy controls (p=0.0001, p=0.001, p=0.003, p=0.014, and p=0.02, respectively). SEB-IgE positivity rates were 45% in SEAwNP, 38% in SEA without NP, 13% in NP without asthma, and 0% in healthy controls. Conclusion: SEAwNP is associated with elevated transcript/protein expression ratio of key T2 inflammatory mediators and increased SEB-IgE positivity, supporting their potential role in the immunopathogenesis of this phenotype. These findings underscore the importance of biomarker profiling in distinguishing endotypes within the spectrum of eosinophilic airway diseases.
- 2 February 2026
- Published by Taylor & Francis in Journal of Asthma
- Vol. 63 (6) , 744-751
Systemic coagulation and fibrinolytic alterations in eosinophilic asthma with and without nasal polyps
ObjectiveAsthma with nasal polyps constitutes a distinct eosinophilic phenotype marked by inflammation and altered coagulation. This study aimed to compare systemic coagulation and fibrinolytic profiles in eosinophilic asthma with and without nasal polyps.MethodsSeventy-two participants were enrolled: eosinophilic asthma with nasal polyps (n = 28), eosinophilic asthma without nasal polyps (n = 22), and age-, sex-, and body mass index-matched healthy controls (n = 22). To minimize confounding, participants were devoid of chronic comorbidities or medications affecting coagulation. Asthma patients were stable on maintenance corticosteroids. Blood eosinophil counts and hemostatic biomarkers [tissue plasminogen activator (tPA), plasminogen activator inhibitor 1 (PAI-1), α2-antiplasmin, D-dimer, fibrinogen, activated partial thromboplastin time (aPTT), international normalized ratio (INR), Factors V and VIII, and thrombin-antithrombin III complex (TAT)] were measured.ResultsCompared with controls, non-polyp asthma showed higher tPA and fibrinogen levels, whereas the nasal polyp subgroup had shorter aPTT and higher PAI-1. TAT levels were significantly lower in the nasal polyp subgroup than in the non-polyp subgroup (p < 0.05). In the overall asthma group, eosinophils correlated negatively with Factor V and PAI-1. Distinctly, the nasal polyp subgroup showed the lowest aPTT and Factor VIII levels, with eosinophils positively correlating with Factor VIII (r = 0.638, p < 0.001).ConclusionEosinophilic asthma with nasal polyps is characterized by distinct hemostatic alterations, including shorter aPTT, higher PAI-1, and lower TAT levels compared to the non-polyp phenotype. These findings suggest a specific link between type 2 inflammation and systemic hemostasis regulation in this subgroup.
- 2 February 2026
- Published by Taylor & Francis in Journal of Asthma
- Vol. 63 (6) , 744-751
Systemic coagulation and fibrinolytic alterations in eosinophilic asthma with and without nasal polyps
ObjectiveAsthma with nasal polyps constitutes a distinct eosinophilic phenotype marked by inflammation and altered coagulation. This study aimed to compare systemic coagulation and fibrinolytic profiles in eosinophilic asthma with and without nasal polyps.MethodsSeventy-two participants were enrolled: eosinophilic asthma with nasal polyps (n = 28), eosinophilic asthma without nasal polyps (n = 22), and age-, sex-, and body mass index-matched healthy controls (n = 22). To minimize confounding, participants were devoid of chronic comorbidities or medications affecting coagulation. Asthma patients were stable on maintenance corticosteroids. Blood eosinophil counts and hemostatic biomarkers [tissue plasminogen activator (tPA), plasminogen activator inhibitor 1 (PAI-1), α2-antiplasmin, D-dimer, fibrinogen, activated partial thromboplastin time (aPTT), international normalized ratio (INR), Factors V and VIII, and thrombin-antithrombin III complex (TAT)] were measured.ResultsCompared with controls, non-polyp asthma showed higher tPA and fibrinogen levels, whereas the nasal polyp subgroup had shorter aPTT and higher PAI-1. TAT levels were significantly lower in the nasal polyp subgroup than in the non-polyp subgroup (p < 0.05). In the overall asthma group, eosinophils correlated negatively with Factor V and PAI-1. Distinctly, the nasal polyp subgroup showed the lowest aPTT and Factor VIII levels, with eosinophils positively correlating with Factor VIII (r = 0.638, p < 0.001).ConclusionEosinophilic asthma with nasal polyps is characterized by distinct hemostatic alterations, including shorter aPTT, higher PAI-1, and lower TAT levels compared to the non-polyp phenotype. These findings suggest a specific link between type 2 inflammation and systemic hemostasis regulation in this subgroup.
- Open Access
- 1 January 2026
- Published by Kare Publishing in Journal of Clinical Practice and Research
- Vol. 48 (1) , 87-91
From Anti-Neutrophil Cytoplasmic Antibody–Negative to Positive: Eosinophilic Granulomatosis with Polyangiitis Under Benralizumab After Steroid Cessation
Background: Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare systemic vasculitis characterized by asthma, eosinophilia, and small- to medium-vessel inflammation. Case Report: We present the case of a 28-year-old woman with severe eosinophilic asthma, chronic rhinosinusitis with nasal polyposis, and recurrent pruritic skin lesions. She was diagnosed with EGPA based on the presence of asthma, peripheral eosinophilia, histopathologically confirmed vasculitis, and sinus-related involvement. Long-term corticosteroid therapy resulted in adverse effects, necessitating a transition to mepolizumab and subsequently to benralizumab. Although systemic corticosteroids were successfully discontinued under benralizumab therapy, the patient developed pruritic papular-plaque skin lesions in the eighth month of treatment. Laboratory evaluation revealed new-onset perinuclear anti-neutrophil cytoplasmic antibody (p-ANCA) positivity despite normal eosinophil counts. Conclusion: This case highlights the importance of close ANCA monitoring and increased awareness of skin manifestations in patients treated with benralizumab in whom systemic corticosteroids can be discontinued.
- 1 January 2026
- Published by Kare Publishing in Journal of Clinical Practice and Research
- Vol. 48 (1) , 87-91
Open AccessFrom Anti-Neutrophil Cytoplasmic Antibody–Negative to Positive: Eosinophilic Granulomatosis with Polyangiitis Under Benralizumab After Steroid Cessation
Background: Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare systemic vasculitis characterized by asthma, eosinophilia, and small- to medium-vessel inflammation. Case Report: We present the case of a 28-year-old woman with severe eosinophilic asthma, chronic rhinosinusitis with nasal polyposis, and recurrent pruritic skin lesions. She was diagnosed with EGPA based on the presence of asthma, peripheral eosinophilia, histopathologically confirmed vasculitis, and sinus-related involvement. Long-term corticosteroid therapy resulted in adverse effects, necessitating a transition to mepolizumab and subsequently to benralizumab. Although systemic corticosteroids were successfully discontinued under benralizumab therapy, the patient developed pruritic papular-plaque skin lesions in the eighth month of treatment. Laboratory evaluation revealed new-onset perinuclear anti-neutrophil cytoplasmic antibody (p-ANCA) positivity despite normal eosinophil counts. Conclusion: This case highlights the importance of close ANCA monitoring and increased awareness of skin manifestations in patients treated with benralizumab in whom systemic corticosteroids can be discontinued.
- 31 December 2025
- Published by Wiley in International Journal of Dermatology
- Vol. 65 (9) , 1838-1845
Dysmenorrhea in Chronic Spontaneous Urticaria: A Subset of Patients Report Worsening and Partial Antihistamine Benefit: UCARE HURDLE ‐I Study
Background: Histamine plays a central role in CSU pathogenesis and may contribute to extracutaneous symptoms such as dysmenorrhea, but this relationship has not been fully examined. Methods: In this prospective, cross‐sectional multicenter study, 425 female CSU patients and 370 age‐matched controls were recruited from 19 UCARE centers in Türkiye. Dysmenorrhea prevalence and severity were assessed using a numerical scale and symptom scores. Histamine skin prick testing (SPT) was performed to evaluate histamine clearance capacity. Associations between dysmenorrhea, CSU phenotype, antihistamine use, and SPT kinetics were analyzed. Results: The prevalence and severity of dysmenorrhea were comparable between CSU patients and controls (81.6% vs. 79.5%, p = 0.244). However, 95/418 (22.7%) of CSU patients reported increased menstrual pain following CSU onset, and 20/95 (21.1%) of these reported partial relief with antihistamines. CSU patients with worsened dysmenorrhea exhibited significantly shorter histamine SPT positivity durations than those without symptom change (35 vs. 45 min; p = 0.015). No correlation was observed between dysmenorrhea severity and total IgE, anti‐TPO levels, or urticaria control/activity scores. A moderate negative correlation was found between UAS7 and elapsed time to histamine SPT negativity ( r = −0.389, p < 0.001). Conclusions: Although overall prevalence and severity of dysmenorrhea were similar in CSU patients and healthy controls, about one in five patients with CSU experienced worsening menstrual pain after disease onset, and only a subset of these patients reported partial improvement with antihistamines. A distinct CSU subgroup with heightened menstrual pain may be characterized by altered histamine dynamics. Whether these patients may benefit from more intensive antihistamine treatment remains uncertain and requires confirmation in future studies; further studies should explore neuroimmune and hormonal mechanisms underlying this overlap.
- 31 December 2025
- Published by Wiley in International Journal of Dermatology
- Vol. 65 (9) , 1838-1845
Dysmenorrhea in Chronic Spontaneous Urticaria: A Subset of Patients Report Worsening and Partial Antihistamine Benefit: UCARE HURDLE ‐I Study
Background: Histamine plays a central role in CSU pathogenesis and may contribute to extracutaneous symptoms such as dysmenorrhea, but this relationship has not been fully examined. Methods: In this prospective, cross‐sectional multicenter study, 425 female CSU patients and 370 age‐matched controls were recruited from 19 UCARE centers in Türkiye. Dysmenorrhea prevalence and severity were assessed using a numerical scale and symptom scores. Histamine skin prick testing (SPT) was performed to evaluate histamine clearance capacity. Associations between dysmenorrhea, CSU phenotype, antihistamine use, and SPT kinetics were analyzed. Results: The prevalence and severity of dysmenorrhea were comparable between CSU patients and controls (81.6% vs. 79.5%, p = 0.244). However, 95/418 (22.7%) of CSU patients reported increased menstrual pain following CSU onset, and 20/95 (21.1%) of these reported partial relief with antihistamines. CSU patients with worsened dysmenorrhea exhibited significantly shorter histamine SPT positivity durations than those without symptom change (35 vs. 45 min; p = 0.015). No correlation was observed between dysmenorrhea severity and total IgE, anti‐TPO levels, or urticaria control/activity scores. A moderate negative correlation was found between UAS7 and elapsed time to histamine SPT negativity ( r = −0.389, p < 0.001). Conclusions: Although overall prevalence and severity of dysmenorrhea were similar in CSU patients and healthy controls, about one in five patients with CSU experienced worsening menstrual pain after disease onset, and only a subset of these patients reported partial improvement with antihistamines. A distinct CSU subgroup with heightened menstrual pain may be characterized by altered histamine dynamics. Whether these patients may benefit from more intensive antihistamine treatment remains uncertain and requires confirmation in future studies; further studies should explore neuroimmune and hormonal mechanisms underlying this overlap.
- 31 December 2025
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 14 (4) , 891-898
Does Asthma Affect Women’s Sexual Life and Marital Adjustment?
- 31 December 2025
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 14 (4) , 891-898
Does Asthma Affect Women’s Sexual Life and Marital Adjustment?
- Open Access
- 12 December 2025
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 55 (6) , 1487-1496
Impact of patient education meetings on disease knowledge in chronic urticaria patients
Background/aim: Chronic urticaria (CU) is a manageable disease with symptoms of itching and visible lesions that can disrupt daily life and reduce quality of life. The severity of symptoms can vary, and the cause is often unknown. Concerns among patients as regards to treatment and prognosis highlight the need for disease education to enhance self-management and reduce anxiety. The present study examines the effect of disease education on the knowledge level of CU patients. Materials and methods: Patients with CU who presented to the allergy clinics of two tertiary university hospitals were invited to inperson education sessions including slide presentations given by faculty members. A 27-question survey was administered before and after the sessions addressing the subject matter, including definitions, causes, diagnostic tests, and treatment options for CU. Results: Included in the study were 83 patients (57 female; 26 male). The average number of correct answers prior to the education session was 13.62, and this increased to 19.48 after education. The most frequently incorrect answers were related to the importance of skin prick tests in cases of urticaria, the daily doses of antihistamines, and the use of topical corticosteroid treatment. The average number of correct answers post-education increased significantly among the university graduates, from 15.45 to 21.72 (p < 0.001), in high school graduates from 11.15 to 17.78 (p < 0.001), and in middle school graduates from 11.71 to 18.14 (p = 0.018). In contrast, the increase was not statistically significant among primary school graduates (p = 0.252). A total of 77 (92%) patients increased their scores after the education session. Conclusion: Patients can benefit from the provision of accurate and reliable information about their disease. Face-to-face education effectively increased knowledge across all educational levels in patients with CU, and reduced their reliance on unreliable online sources. This enhanced understanding is expected to lead to better treatment adherence and self-management skills.
- 12 December 2025
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 55 (6) , 1487-1496
Open AccessImpact of patient education meetings on disease knowledge in chronic urticaria patients
Background/aim: Chronic urticaria (CU) is a manageable disease with symptoms of itching and visible lesions that can disrupt daily life and reduce quality of life. The severity of symptoms can vary, and the cause is often unknown. Concerns among patients as regards to treatment and prognosis highlight the need for disease education to enhance self-management and reduce anxiety. The present study examines the effect of disease education on the knowledge level of CU patients. Materials and methods: Patients with CU who presented to the allergy clinics of two tertiary university hospitals were invited to inperson education sessions including slide presentations given by faculty members. A 27-question survey was administered before and after the sessions addressing the subject matter, including definitions, causes, diagnostic tests, and treatment options for CU. Results: Included in the study were 83 patients (57 female; 26 male). The average number of correct answers prior to the education session was 13.62, and this increased to 19.48 after education. The most frequently incorrect answers were related to the importance of skin prick tests in cases of urticaria, the daily doses of antihistamines, and the use of topical corticosteroid treatment. The average number of correct answers post-education increased significantly among the university graduates, from 15.45 to 21.72 (p < 0.001), in high school graduates from 11.15 to 17.78 (p < 0.001), and in middle school graduates from 11.71 to 18.14 (p = 0.018). In contrast, the increase was not statistically significant among primary school graduates (p = 0.252). A total of 77 (92%) patients increased their scores after the education session. Conclusion: Patients can benefit from the provision of accurate and reliable information about their disease. Face-to-face education effectively increased knowledge across all educational levels in patients with CU, and reduced their reliance on unreliable online sources. This enhanced understanding is expected to lead to better treatment adherence and self-management skills.
- 1 September 2025
- Published by Codon Publications in Allergologia et Immunopathologia
- Vol. 53 (5) , 94-99
Can fluoroquinolones be safely used in patients with immediate hypersensitivity reaction to penicillin?
Objective: The aim of this study was to evaluate whether fluoroquinolone antibiotics, which are structurally distinct from penicillins, can be safely prescribed as alternatives for patients with a history of immediate-type hypersensitivity reactions (HSRs) to penicillin in the absence of multidrug allergy and without the need for provocation testing. Methods: We conducted a retrospective analysis of the medical records of patients who presented to the Erciyes University Adult Immunology and Allergy Outpatient Clinic with a documented history of penicillin allergy between 2015 and 2024. Inclusion criteria for immediate hypersensitivity to penicillin included at least one of the following: (1) a history of at least two separate immediate HSRs to the same penicillin; or (2) positive results from penicillin G/V (Penicillin G and Penicillin V) serum-specific immunoglobulin E (SsIgE) and/or skin prick testing. Patients who met these criteria and subsequently underwent oral provocation testing with fluoroquinolone antibiotics were included in the study. Results: This study included 76 patients (72% female, mean age: 45.63 ± 11.76 years), 47.4% of whom had comorbid allergic diseases. The diagnosis was primarily based on clinical history (80%), while the remainder were confirmed by SsIgE testing, skin tests, or drug provocation. A history of urticaria-angioedema was reported in 59.2% of the patients, while 40.8% had a history of anaphylaxis. Following oral provocation testing with fluoroquinolones, only two patients (2.6%) developed mild, self-limited urticaria or angioedema, without systemic involvement. Conclusions: Our study demonstrates a low positive rate (2.6%) for fluoroquinolone oral provocation testing among patients with penicillin allergy. These findings suggest that fluoroquinolones may be a viable and safe alternative in patients with a confirmed penicillin hypersensitivity and no history of multidrug allergy, and may be considered without prior provocation testing in selected cases.
- 1 September 2025
- Published by Codon Publications in Allergologia et Immunopathologia
- Vol. 53 (5) , 94-99
Can fluoroquinolones be safely used in patients with immediate hypersensitivity reaction to penicillin?
Objective: The aim of this study was to evaluate whether fluoroquinolone antibiotics, which are structurally distinct from penicillins, can be safely prescribed as alternatives for patients with a history of immediate-type hypersensitivity reactions (HSRs) to penicillin in the absence of multidrug allergy and without the need for provocation testing. Methods: We conducted a retrospective analysis of the medical records of patients who presented to the Erciyes University Adult Immunology and Allergy Outpatient Clinic with a documented history of penicillin allergy between 2015 and 2024. Inclusion criteria for immediate hypersensitivity to penicillin included at least one of the following: (1) a history of at least two separate immediate HSRs to the same penicillin; or (2) positive results from penicillin G/V (Penicillin G and Penicillin V) serum-specific immunoglobulin E (SsIgE) and/or skin prick testing. Patients who met these criteria and subsequently underwent oral provocation testing with fluoroquinolone antibiotics were included in the study. Results: This study included 76 patients (72% female, mean age: 45.63 ± 11.76 years), 47.4% of whom had comorbid allergic diseases. The diagnosis was primarily based on clinical history (80%), while the remainder were confirmed by SsIgE testing, skin tests, or drug provocation. A history of urticaria-angioedema was reported in 59.2% of the patients, while 40.8% had a history of anaphylaxis. Following oral provocation testing with fluoroquinolones, only two patients (2.6%) developed mild, self-limited urticaria or angioedema, without systemic involvement. Conclusions: Our study demonstrates a low positive rate (2.6%) for fluoroquinolone oral provocation testing among patients with penicillin allergy. These findings suggest that fluoroquinolones may be a viable and safe alternative in patients with a confirmed penicillin hypersensitivity and no history of multidrug allergy, and may be considered without prior provocation testing in selected cases.
- 5 July 2025
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 317 (1) , 1-6
Interval prolongation is an effective and well-tolerated approach when stepping down omalizumab treatment in chronic spontaneous urticaria
- 5 July 2025
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 317 (1) , 1-6
Interval prolongation is an effective and well-tolerated approach when stepping down omalizumab treatment in chronic spontaneous urticaria
- 15 May 2025
- Published by Taylor & Francis in Journal of Asthma
- Vol. 62 (9) , 1512-1524
Distinct characteristics of asthma overlap phenotypes: Insights from the Turkish adult asthma registry
Considerable overlaps exist between asthma phenotypes and the clinical significance of these overlaps remains undetermined. The objective of this study is to analyze the characteristics of asthma overlap phenotypes using data from the Turkish Adult Asthma Registry (TAAR). This cross-sectional registry study included 2053 adult patients (74.8% female) with asthma. Overall, 39.3% (n = 697) had allergic-eosinophilic (AE), 26.0% (n = 461) had allergic-non-eosinophilic (ANE), 21.3% (n = 377) had non-allergic-eosinophilic (NAE), and 13.4% (n = 237) had non-allergic-non-eosinophilic (NANE) asthma. Severe asthma exacerbations and emergency department (ED) visits were more frequent in the AE (28.3%, 31.2%, respectively) and NAE groups (36.0%, 34.0%, respectively) than in the ANE (14.3%, 20.6%, respectively) and NANE groups (12.6%, 16.7%, respectively) (p < 0.001). FEV1 values were significantly lower in the AE group than in the ANE and NANE groups (p < 0.001, p = 0.048, respectively) and in the NAE group than in the ANE group (p < 0.001). Risk factors for poor asthma control included living in rural areas, asthma-related ED visits, FEV1 < 60% in the NAE; being overweight, chronic rhinosinusitis, oral corticosteroids use, age < 40 years in the NANE; FEV1 < 80% in the AE; and severe asthma exacerbations, ED visits for AE and ANE groups. The considerable overlap between allergic and eosinophilic asthma phenotypes has clinical implications as increased rates of asthma exacerbations and healthcare utilization. The clinical heterogeneity among asthma phenotypes based on a single biomarker highlights the importance of multidimensional asthma phenotyping.
- 15 May 2025
- Published by Taylor & Francis in Journal of Asthma
- Vol. 62 (9) , 1512-1524
Distinct characteristics of asthma overlap phenotypes: Insights from the Turkish adult asthma registry
Considerable overlaps exist between asthma phenotypes and the clinical significance of these overlaps remains undetermined. The objective of this study is to analyze the characteristics of asthma overlap phenotypes using data from the Turkish Adult Asthma Registry (TAAR). This cross-sectional registry study included 2053 adult patients (74.8% female) with asthma. Overall, 39.3% (n = 697) had allergic-eosinophilic (AE), 26.0% (n = 461) had allergic-non-eosinophilic (ANE), 21.3% (n = 377) had non-allergic-eosinophilic (NAE), and 13.4% (n = 237) had non-allergic-non-eosinophilic (NANE) asthma. Severe asthma exacerbations and emergency department (ED) visits were more frequent in the AE (28.3%, 31.2%, respectively) and NAE groups (36.0%, 34.0%, respectively) than in the ANE (14.3%, 20.6%, respectively) and NANE groups (12.6%, 16.7%, respectively) (p < 0.001). FEV1 values were significantly lower in the AE group than in the ANE and NANE groups (p < 0.001, p = 0.048, respectively) and in the NAE group than in the ANE group (p < 0.001). Risk factors for poor asthma control included living in rural areas, asthma-related ED visits, FEV1 < 60% in the NAE; being overweight, chronic rhinosinusitis, oral corticosteroids use, age < 40 years in the NANE; FEV1 < 80% in the AE; and severe asthma exacerbations, ED visits for AE and ANE groups. The considerable overlap between allergic and eosinophilic asthma phenotypes has clinical implications as increased rates of asthma exacerbations and healthcare utilization. The clinical heterogeneity among asthma phenotypes based on a single biomarker highlights the importance of multidimensional asthma phenotyping.